RTP Mobile Logo
Select Publications

Sara Hurvitz, MD

Mittendorf EA et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet 2020;396(10257):1090-100. Abstract

Schmid P et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382(9):810-21. Abstract

Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394-405. Abstract

Rita Nanda, MD

Alva AS et al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 2021;39(22):2243-51. Abstract

Cortés J et al. KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. ESMO 2021;Abstract LBA16.

Winer EP et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(4):499-511. Abstract

Hope S Rugo, MD

Bardia A et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384(16):1529-41. Abstract

Krop I et al. Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study. SABCS 2021;Abstract GS1-05.

Schettini F et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021;7(1):1. Abstract

Melinda Telli, MD

Diéras V et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(10):1269-82. Abstract

Litton JK et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial. Ann Oncol 2020;31(11):1526-35. Abstract

Tung NM et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 2020;38(36):4274-82. Abstract